Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $1.90M | $1.09M | $4.14M | $4.60M | $4.94M |
| Revenue growth | — | — | -42.8% | 279.6% | 11.2% | 7.5% |
| Gross profit | — | — | $544K | $1.40M | $1.10M | $1.71M |
| Gross margin | — | — | 49.9% | 33.9% | 23.9% | 34.5% |
| Operating income | — | -$10.2M | -$18.6M | -$7.95M | — | — |
| Operating margin | — | -535.9% | -1707.3% | -192.2% | — | — |
| Net income | -$8.94M | -$10.2M | -$18.6M | -$7.95M | -$7.68M | -$8.16M |
| Net margin | — | -535.9% | -1707.3% | -192.2% | -166.9% | -165.1% |
| EPS (diluted) | -$1.71 | -$37.96 | -$33.17 | -$3.25 | -$20.14 | -$8.36 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.37M | -$9.79M | -$15.6M | -$7.28M | -$6.99M | -$7.77M |
| Capital expenditures | $42.6K | $1.73K | $39.1K | $160K | $9.29K | — |
| Free cash flow | -$7.42M | -$9.79M | -$15.6M | -$7.44M | -$7.00M | — |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $5.81M | $7.36M | $6.18M | $8.91M | $6.57M | $11.1M |
| Total assets | $7.80M | $9.78M | $12.8M | $14.1M | $11.8M | $15.6M |
| Total liabilities | $1.92M | $2.40M | $3.71M | $2.02M | $2.62M | $2.15M |
| Shareholders' equity | $5.88M | $7.38M | $9.08M | $12.1M | $9.21M | $13.4M |
| Retained earnings | -$64.6M | -$74.9M | -$93.5M | -$101M | -$109M | -$117M |
| Shares (wtd avg diluted) | 5.22M | 269K | 561K | 2.45M | 381K | 976K |
Every figure is extracted from InMed Pharmaceuticals Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.